BRAF and neoplasm: ATC harbors BRAF p.V600E (25.9–45.0%) and RAS mutations (24.0–40.7%) as early molecular events, while TP53 (40–80%) and TERT promoter mutations (30–75%) are additional late molecular events and the most frequent genetic changes seen in this tumor [45, 46].